Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers

Abstract To evaluate the role of the vitreous in the management of diabetic macular edema with ranibizumab intravitreal injections in a pro re nata regimen. Prospective study of 50 consecutive eyes with diabetic macular edema treated with ranibizumab and 12 months of follow-up. Primary endpoint: to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bernardete Pessoa, João Leite, João Heitor, João Coelho, Sérgio Monteiro, Constança Coelho, João Figueira, Angelina Meireles, João Nuno Melo-Beirão
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f2d4703c5f8848a1ae7df737c3a2cac4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2d4703c5f8848a1ae7df737c3a2cac4
record_format	dspace
spelling	oai:doaj.org-article:f2d4703c5f8848a1ae7df737c3a2cac42021-12-05T12:12:51ZVitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers10.1038/s41598-021-02532-42045-2322https://doaj.org/article/f2d4703c5f8848a1ae7df737c3a2cac42021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-02532-4https://doaj.org/toc/2045-2322Abstract To evaluate the role of the vitreous in the management of diabetic macular edema with ranibizumab intravitreal injections in a pro re nata regimen. Prospective study of 50 consecutive eyes with diabetic macular edema treated with ranibizumab and 12 months of follow-up. Primary endpoint: to assess differences between non-vitrectomized and vitrectomized eyes in the number injections needed to control the edema. Secondary endpoints: comparison of groups regarding best corrected visual acuity, central foveal thickness and thickness of seven retinal layers. 46 eyes from 38 patients, 10 vitrectomized and 36 non-vitrectomized, completed the follow-up. At month 12, the two groups achieved an equivalent anatomical outcome and needed a similar number of ranibizumab intravitreal injections. In vitrectomized eyes final visual acuity was worse when baseline retinal nerve fiber layers in the central foveal subfield were thicker, showing a strong correlation (r = − 0.942, p < 0.001). A similar, albeit moderate correlation was observed in non-vitrectomized eyes (r = − 0.504, p = 0.002). A decrease of retinal nerve fiber layers inner ring thickness was correlated with a better final visual acuity only in vitrectomized eyes (r = 0.734, p = 0.016). The effect of diabetic macular edema seems to be worse in vitrectomized eyes, with a thinner inner retina reservoir. Clinicaltrials.govNCT04387604.Bernardete PessoaJoão LeiteJoão HeitorJoão CoelhoSérgio MonteiroConstança CoelhoJoão FigueiraAngelina MeirelesJoão Nuno Melo-BeirãoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Bernardete Pessoa João Leite João Heitor João Coelho Sérgio Monteiro Constança Coelho João Figueira Angelina Meireles João Nuno Melo-Beirão Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
description	Abstract To evaluate the role of the vitreous in the management of diabetic macular edema with ranibizumab intravitreal injections in a pro re nata regimen. Prospective study of 50 consecutive eyes with diabetic macular edema treated with ranibizumab and 12 months of follow-up. Primary endpoint: to assess differences between non-vitrectomized and vitrectomized eyes in the number injections needed to control the edema. Secondary endpoints: comparison of groups regarding best corrected visual acuity, central foveal thickness and thickness of seven retinal layers. 46 eyes from 38 patients, 10 vitrectomized and 36 non-vitrectomized, completed the follow-up. At month 12, the two groups achieved an equivalent anatomical outcome and needed a similar number of ranibizumab intravitreal injections. In vitrectomized eyes final visual acuity was worse when baseline retinal nerve fiber layers in the central foveal subfield were thicker, showing a strong correlation (r = − 0.942, p < 0.001). A similar, albeit moderate correlation was observed in non-vitrectomized eyes (r = − 0.504, p = 0.002). A decrease of retinal nerve fiber layers inner ring thickness was correlated with a better final visual acuity only in vitrectomized eyes (r = 0.734, p = 0.016). The effect of diabetic macular edema seems to be worse in vitrectomized eyes, with a thinner inner retina reservoir. Clinicaltrials.govNCT04387604.
format	article
author	Bernardete Pessoa João Leite João Heitor João Coelho Sérgio Monteiro Constança Coelho João Figueira Angelina Meireles João Nuno Melo-Beirão
author_facet	Bernardete Pessoa João Leite João Heitor João Coelho Sérgio Monteiro Constança Coelho João Figueira Angelina Meireles João Nuno Melo-Beirão
author_sort	Bernardete Pessoa
title	Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
title_short	Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
title_full	Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
title_fullStr	Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
title_full_unstemmed	Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
title_sort	vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f2d4703c5f8848a1ae7df737c3a2cac4
work_keys_str_mv	AT bernardetepessoa vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT joaoleite vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT joaoheitor vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT joaocoelho vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT sergiomonteiro vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT constancacoelho vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT joaofigueira vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT angelinameireles vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers AT joaonunomelobeirao vitrectomizedversusnonvitrectomizedeyesindiabeticmacularedemaresponsetoranibizumabretinallayersthicknessasprognosticbiomarkers
_version_	1718372170138124288

Vitrectomized versus non-vitrectomized eyes in diabetic macular edema response to ranibizumab—retinal layers thickness as prognostic biomarkers

Ejemplares similares